Keywords: aventis, results, line, expectations, firm, cuts, forecast
Aventis 2002 results in line with expectations, but firm cuts 2003 forecast
Article | 10 February 2003
Franco-German drug major Aventis reported a strong set of results forfull-year 2002, with group net income leaping 38.9% to 2.09 billion euros ($2.25 billion) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
